BOSTON/NEW YORK (Reuters) –
U.S. health-care firm Johnson & Johnson (JNJ.N) is in talks to cut the price of a $1.5 billion deal with Irish drugmaker Elan Corp (ELN.I), a source familiar with the negotiations said on Sunday.
J&J agreed in July to pay $1 billion for an 18.4 percent stake in Elan and $500 million for a majority stake in its pipeline of experimental Alzheimer's drugs.
However, Elan and J&J had been widely expected to renegotiate the deal after a court ruled the agreement breached a partnership between Elan and Biogen Idec Inc (BIIB.O).
A U.S. judge earlier in September ruled that the deal — which has not yet closed — breaches Elan's 50-50 partnership to sell multiple sclerosis drug Tysabri with Biogen, a Cambridge, Massachusetts-based biotech company whose shareholders include billionaire investor Carl Icahn.
The Wall Street Journal reported on Sunday that J&J is attempting to cut at least $100 million off the $1 billion in cash it agreed to pay as part of the deal and that the new terms could be announced in the coming days.
J&J was not immediately available for comment. Elan declined comment.
(Reporting by Toni Clarke in Boston, writing and additional reporting by Megan Davies in New York; Editing by Diane Craft)
Popularity: unranked [?]
An 8.2-metre optical telescope which forms part of the VLT (Very Large Telescope) in Chile European Southern Observatory astronomers have said they had uncovered the oldest stars in our galactic neighborhood thanks to a massive telescope installed in Chile...
Are they ancient road maps or messages for visiting aliens? Lying at the foothill of Peru’s Andes Mountains is the site of one of the world’s greatest mysteries...
‘ Zahangir Kabir A solar array about the size of one percent the size of the Sahara Desert is good enough to supply the whole world with electric power...